Disc Medicine Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
IRON$84.64+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
CONSOLIDATED STATEMENTS STOCKHOLDERS’ EQUITY
| Common Stock$0.0001 Par Value · · Additional Paid-In · Accumulated OtherComprehensive · Accumulated · TotalStockholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | | Amount | | Capital | Income | Deficit | Equity | |
| Balance at December 31, 2022 | 17,403,315 | $2 | $288,814 | $— | $(112,216) | $176,600 | ||
| Issuance of common stock upon exercise of stock options | 254,432 | — | 2,763 | — | — | 2,763 | ||
| Vesting of restricted common stock | 1,916 | — | — | — | — | — | ||
| Stock-based compensation expense | — | — | 5,530 | — | — | 5,530 | ||
| Sale of common stock in registered direct offering, net of issuance costs of $80 | 1,488,166 | — | 34,148 | — | — | 34,148 | ||
| Sale of pre-funded warrants in registered direct offering, net of issuance costs of $66 | — | — | 28,206 | — | — | 28,206 | ||
| Sale of common stock in at-the-market offerings, net of issuance costs of $742 | 967,264 | — | 26,422 | — | — | 26,422 | ||
| Sale of common stock in follow-on public offering, net of issuance costs of $9,272 | 3,015,919 | — | 138,508 | — | — | 138,508 | ||
| Sale of pre-funded warrants in follow-on public offering, net of issuance costs of $627 | — | — | 9,373 | — | — | 9,373 | ||
| Issuance of common stock upon exercise of warrants | 1,229,221 | — | — | — | — | — | ||
| Net loss | — | — | — | — | (76,429) | (76,429) | ||
| Balance at December 31, 2023 | 24,360,233 | $2 | $533,764 | $— | $(188,645) | $345,121 | ||
| Issuance of common stock upon exercise of stock options | 315,266 | — | 2,976 | — | — | — | 2,976 | |
| Stock-based compensation expense | — | — | 16,815 | — | — | — | 16,815 | |
| Sale of common stock in at-the-market offerings, net of issuance costs of $518 | 234,449 | — | 14,790 | — | — | — | 14,790 | |
| Sale of common stock in an underwritten offering, net of issuance costs of $5,472 | 4,944,000 | 1 | 172,511 | — | — | — | 172,512 | |
| Issuance of common stock under employee stock purchase plan | 11,082 | — | 441 | — | — | — | 441 | |
| Foreign currency translation adjustments | — | — | — | (27) | — | — | (27) | |
| Unrealized gain on marketable securities | — | — | — | 316 | — | — | 316 | |
| Net loss | — | — | — | — | (109,357) | — | (109,357) | |
| Balance at December 31, 2024 | 29,865,030 | $3 | $741,297 | $289 | $(298,002) | $443,587 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.